purpose assess safety potential toxicity proton beam radiation treatment subfoveal choroidal neovascular membrane cnvm manner degeneration armd prospective study methods eyes NUMBER consecutive patients subfoveal cnvm armd amenable laser photocoagulation treated prospectively single proton beam exposure dose regimens evaluated NUMBER cge cobalt gray equivalent NUMBER cge patients followed average NUMBER months proton beam treatment results NUMBER month NUMBER eyes NUMBER cge group NUMBER eyes NUMBER cge group stabilized improved visual acuity complex size NUMBER cge group measured standard fluorescein angiography fa decreased change initially showed effect time eyes treated NUMBER cge maintained decreased leakage period NUMBER months NUMBER eyes NUMBER cge group experienced radiation retinopathy onset NUMBER NUMBER months seven NUMBER eyes demonstrated visual loss NUMBER eye developed severe visual loss NUMBER months proton treatment conclusions date NUMBER cge suggested favourable influence visual function growth inhibition cnvm proton beam irradiation appears inhibit cnvm growth NUMBER cge dose regimen appears longer effect cnvm growth does NUMBER cge overall stabilisation visual function growth inhibition radiation retinopathy developed time severe visual loss limited basis incidence radiation retinopathy adjustments total radiation dosage fractionation dosage considered age related non randomised follow follow